Omnicell, Inc.
NASDAQ:OMCLMedical - Healthcare Information Services
-$0.58 today
- Market cap
- $1.59B
- Beta
- 0.96
- P/E (TTM)
- 84.1
- EPS (TTM)
- $0.45
Volume 0.34M
Average 0.57M
OMCL Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Omnicell, Inc.NASDAQ: OMCL
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $20.5M fell 6.1% year over year, in line with the -5.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 3.5% from the prior quarter. Over 3 fiscal years it compounded at -4.4% a year.
Context
- Depreciation & amortization amounted to 7.3% of revenue in FY2025, down 0.8 pp from a year earlier.
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -6.1% toward the trailing-twelve-month pace of -5.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 86.63M USD
- Year-over-year change
- -3.5%
- 4-year CAGR
- +0.5%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 86.63M | -3.5% |
| FY2024 | 2024-12-31 | 89.76M | -6.1% |
| FY2023 | 2023-12-31 | 95.56M | -3.6% |
| FY2022 | 2022-12-31 | 99.17M | +16.8% |
| FY2021 | 2021-12-31 | 84.93M | — |
Depreciation & Amortization vs competitors
How OMCL compares with its peers on the latest reported figures
- OMCL's LTM Mar 2026 depreciation & amortization of $83.32M is the 2nd largest of the 11 companies compared; the peer median is $27.1M.
- Its year-over-year change of -5.8% is the 10th highest of 11, against a peer median of +17.8%.
- Depreciation & amortization amounts to 6.8% of revenue for OMCL, versus a peer median of 2.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $370.85M | -0.4% | +10.7% | 14.7% | |
| LTM Mar 2026 | $83.32M | -5.8% | -4.4% | 6.8% | |
| LTM Mar 2026 | $82.56M | +10.8% | +16.3% | 10.5% | |
| LTM Mar 2026 | $54.38M | +83.2% | +37.6% | 1.5% | |
| LTM Jun 2026 | $45.93M | +12.6% | +9.9% | 7.4% | |
| LTM Apr 2026 | $34.53M | +22.9% | +7.5% | 7.0% | |
| LTM Jun 2026 | $19.66M | +9.0% | +17.2% | 3.1% | |
| LTM Jun 2026 | $7.22M | +79.8% | +45.7% | 0.6% | |
| LTM Mar 2026 | $6.61M | +31.8% | +8.2% | 2.3% | |
| LTM Sep 2026 | $5.86M | -7.7% | +11.5% | 2.2% | |
| LTM Mar 2026 | $1.19M | +110.8% | +123.3% | 2.5% | |
| Peer median (excluding OMCL) | $27.1M | +17.8% | +13.9% | 2.8% | |
Competitors are the stored peer set for OMCL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 77.85M | 5.65M | (20.37M) | 12.53M | 2.05M |
| Depreciation & Amortization | 84.93M | 99.17M | 95.56M | 89.76M | 86.63M |
| Deferred Income Tax | (3.27M) | (37.32M) | (11.05M) | (14.86M) | (1.29M) |
| Stock-Based Compensation | 53.16M | 68.25M | 55.3M | 39.32M | 44.5M |
| Change in Working Capital | (3.34M) | (73.47M) | 43.67M | 58.33M | (8.33M) |
| Accounts Receivables | (40.97M) | (60.36M) | 38.74M | (5M) | 41.42M |
| Inventory | (25.7M) | (30.12M) | 38.02M | 5.39M | (11.23M) |
| Accounts Payables | 29.08M | (7.75M) | (17.53M) | 7.21M | (9.28M) |
| Other Working Capital | 34.24M | 24.76M | (15.56M) | 50.73M | (29.25M) |
| Other Non-Cash Items | 22.48M | 15.5M | 17.98M | 2.64M | 3.74M |
| Operating Cash Flow | 231.81M | 77.78M | 181.09M | 187.72M | 127.3M |
| Capital Expenditures | (28.97M) | (60.74M) | (41.47M) | (36.46M) | (40.42M) |
| Acquisitions (Net) | (354.16M) | 2.07M | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | (15.35M) | 0 | (10.4M) | (10.17M) |
| Other Investing Activities | (29.37M) | 15.35M | 0 | (5.93M) | (9.78M) |
| Investing Cash Flow | (412.5M) | (58.67M) | (55.02M) | (52.79M) | (60.36M) |
| Debt Repayment | 0 | 0 | (2.97M) | (225.46M) | (175M) |
| Common Stock Issued | 0 | 40.18M | 23.22M | 38.58M | 16.87M |
| Common Stock Repurchased | (16.29M) | (52.21M) | 0 | 0 | (77.6M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 63.65M | (8.93M) | 3.17M | (48.7M) | 17.42M |
| Financing Cash Flow | 47.36M | (20.95M) | 23.42M | (235.58M) | (218.32M) |
| Effect of Forex Changes | (974K) | (944K) | (1.35M) | (1.72M) | 3.8M |
| Net Change in Cash | (134.3M) | (2.79M) | 148.14M | (102.37M) | (147.58M) |
| Free Cash Flow | 202.84M | 17.04M | 139.62M | 151.26M | 86.89M |
Omnicell, Inc.
NASDAQ:OMCL
Intrinsic Alpha fair value
Locked
Current Price
$34.66
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.